The FDA granted marketing approval for Cytokinetics’ aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy in adults, clearing multiple tablet strengths. The approval positions Cytokinetics to compete with Bristol Myers Squibb’s allosteric myosin inhibitor Camzyos. Prescribing information includes a boxed warning for potential heart‑failure risk due to reductions in left ventricular ejection fraction; monitoring and risk‑management requirements differ from BMS’ product, which analysts say could affect uptake. Sources: Cytokinetics, FDA release and market commentary.